Coronavirus Disease 2019 (COVID-19) Outbreak, Update # 42
Update on Johnson & Johnson (J&J) Janssen COVID-19 Vaccine

- The CDC and FDA have lifted the national “pause” on use of the Johnson and Johnson (J&J) Janssen COVID-19 vaccine and recommend that use of this vaccine resume for people 18 years of age and older.
  - There are no new recommended restrictions on use based on age, gender, or risk factors; however, clinicians need to be aware of the potential very low risk of thrombosis and thrombocytopenia syndrome (TTS) and appropriately inform vaccine recipients (see below).
- The CDC’s Advisory Committee on Immunization Practices (ACIP) met today to review updated information about cases of TTS after the J&J Janssen vaccine.
  - Meeting information, including presented data, can be found online: https://www.cdc.gov/vaccines/acip/meetings/slides-2021-04-23.html
  - Experts believe that the pathogenesis of TTS is similar to autoimmune heparin induced thrombocytopenia (HIT), but the exact mechanism of the syndrome after receipt of the J&J Janssen vaccine is not yet known
  - The risk of TTS after receipt of the J&J Janssen vaccine is believed to be very low, and ongoing investigation continues
  - No cases of TTS have been identified after receipt of the Moderna or Pfizer-BioNTech mRNA COVID-19 vaccines
- As of April 21st, there have been 15 confirmed TTS cases out of 7.98 million J&J Janssen COVID-19 vaccine doses administered (1.9 cases per million people vaccinated). All have been in females, the majority of which were aged 18-49 years of age (n=13); 3 people have died.
  - The rate of TTS in females aged 18-49 years of age is 7.0 cases per million vaccinated
  - Median age is 37 years (range 18-59)
  - Median time to symptom onset is 8 days (range 6-15 days)
  - No cases have occurred in pregnant or post-partum women
  - 12 cases of TTS involved cerebral venous sinus thrombosis (CVST)
  - Other contributing risk factors for TTS after J&J Janssen vaccination are not known
- Clinicians can resume use of the J&J Janssen vaccine, but should inform patients about the potential, but very low, risk of TTS after receipt of the J&J Janssen vaccine. The FDA and CDC are updating guidance to assist with informing vaccine recipients about potential risks:
  - FDA Fact Sheet for Recipients and Caregivers has been updated
  - FDA Fact Sheet for Healthcare Providers Administering Vaccine has been updated
  - A Morbidity and Mortality Weekly Report (MMWR) is planned for Tuesday with further information about TTS and the J&J Janssen vaccine
  - CDC is updating their Interim Clinical Considerations for Use of COVID-19 Vaccines
o CDC is also planning on develop additional messaging material to help inform clinicians and patients about potential risk for TTS with use of the J&J Janssen vaccine

o A webinar to update clinicians on the latest evidence on TTS after administration of the J&J Janssen COVID-19 vaccine is occurring on Tuesday, April 27th from 2:00 – 3:00 PM; call information can be found at: https://emergency.cdc.gov/coca/calls/2021/callinfo_042721.asp.

• In patients with suspected TTS after receipt of the J&J Janssen vaccine, consultation with a hematologist is strongly recommended to assist with diagnosis and management

  o The American Society of Hematology has developed guidance for assessment and management of TTS identified after receipt of the J&J Janssen vaccine: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia

• Health care providers are asked to report adverse events, including suspected cases of TTS, to the Vaccine Adverse Event Reporting System (VAERS).

• See CDC Health Alert issued on April 13, 2021 for more background information and guidance: https://emergency.cdc.gov/han/2021/han00442.asp.

Weekly Partner Calls For:

• Long-term care facilities and congregate living settings first and third Wednesdays from 11:45 am – 1:00 pm, in partnership with the NH Healthcare Association (NHHCA):
  o Zoom: https://zoom.us/j/511075725
  o Call-in phone number: (929) 205-6099
  o Meeting ID: 511 075 725
  o Password: 092020

• Educational and childcare partners first and third Wednesdays from 3:30 – 4:30 pm:
  o Zoom link: https://nh-dhhs.zoom.us/j/98062195081
  o Call-in phone number: (646) 558-8656
  o Meeting ID: 980 6219 5081
  o Password: 197445

• Healthcare providers and other public health partners every Thursday from 12:00 – 1:00 pm; these calls focus on new science, medical, and vaccine updates:
  o Zoom link: https://zoom.us/s/94841259025
  o Call-in phone number: (646) 558-8656
  o Meeting ID: 948 4125 9025
  o Password: 003270
For any questions regarding this notification, please call the NH DHHS, DPHS, Bureau of Infectious Disease Control at (603) 271-4496 during business hours (8:00 a.m. – 4:30 p.m.)

If you are calling after hours or on the weekend, please call the New Hampshire Hospital switchboard at (603) 271-5300 and request the Public Health Professional on-call

To change your contact information in the NH Health Alert Network, please send an email to DHHS.Health.Alert@dhhs.nh.gov

Status: Actual
Message Type: Alert
Severity: Moderate
Sensitivity: Not Sensitive
Message Identifier: NH-HAN 20210423 COVID-19 Update 42
Delivery Time: 12 hours
Acknowledgement: No
Distribution Method: Email, Fax
Distributed to: Physicians, Physician Assistants, Practice Managers, Infection Control Practitioners, Infectious Disease Specialists, Community Health Centers, Hospitals, Hospital CEOs, Hospital Emergency Departments, EMS, Nurses, NHHA, Pharmacists, Laboratory Response Network, Manchester Health Department, Nashua Health Department, Public Health Networks, DHHS Outbreak Team, DPHS Investigation Team, DPHS Management Team, Northeast State Epidemiologists, Zoonotic Alert Team, Health Officers, Deputy Health Officers, MRC, NH Schools, EWIDS, Dialysis & Transplant Clinics, STD Clinics, Immunization Practices, Travel Centers, Influenza Sentinels, Urgent Care Centers, Ambulatory Surgical Centers, Walk-in Clinics, Poison Center, Alcohol and Other Drug Treatment Centers, Long-Term Care Facilities, Community Mental Health Centers, Health Departments, Internal Medicine, Occupational Health, Gastroenterology, Schools and Daycare Providers, Regional Public Health Networks, Environmental Services, Family Planning Programs, Department of Corrections, Home Care Providers, Local and State Partners, Area Agencies

From: Benjamin P. Chan, MD, MPH; State Epidemiologist
Originating Agency: NH Department of Health and Human Services, Division of Public Health Services